Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Finished Goods: 2022-2025

Historic Finished Goods for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to $10.3 million.

  • Axsome Therapeutics' Finished Goods rose 17.28% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 17.28%. This contributed to the annual value of $9.0 million for FY2024, which is 6.81% down from last year.
  • Axsome Therapeutics' Finished Goods amounted to $10.3 million in Q3 2025, which was up 8.90% from $9.5 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Finished Goods high stood at $10.3 million for Q3 2025, and its period low was $1.6 million during Q4 2022.
  • Its 3-year average for Finished Goods is $9.0 million, with a median of $9.0 million in 2025.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 506.48% in 2023, then declined by 12.00% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Finished Goods (Quarterly) stood at $1.6 million in 2022, then spiked by 506.48% to $9.6 million in 2023, then fell by 6.81% to $9.0 million in 2024, then increased by 17.28% to $10.3 million in 2025.
  • Its Finished Goods was $10.3 million in Q3 2025, compared to $9.5 million in Q2 2025 and $9.0 million in Q1 2025.